We show here that an increased proportion of tamoxifen-resistant CBCs, i. e. tumors developed during adjuvant tamoxifen treatment, were HIF-1α positive and that HIF-1α-positivity in the tumors led to increased breast cancer mortality (BCM). The gene discussed is HIF1A; the disease is breast carcinoma.